Condition: Eosinophilic Asthma · Sponsor: Kymera Therapeutics, Inc.
This Phase 2b study is designed to evaluate the safety and efficacy of KT-621 in participants with uncontrolled moderate to severe eosinophilic asthma. The main goals of this study are to investigate how effective KT-621 is at treating uncontrolled moderate to severe eosinophilic asthma, the safety and tolerability of KT-621, and how KT-621 behaves in the body.
This description comes directly from the study's public registry record.
Kymera Medical Director · 857-285-5300 · clinicaltrials@kymeratx.com
Always discuss trial participation with your own doctor first.
| Kymera Investigative Site | Lancaster, California, United States | Recruiting |
| Kymera Investigative Site | Long Beach, California, United States | Recruiting |
| Kymera Investigative Site | Northridge, California, United States | Recruiting |
| Kymera Investigative Site | Redding, California, United States | Recruiting |
| Kymera Investigative Site | Upland, California, United States | Recruiting |
| Kymera Investigative Site | Loxahatchee Groves, Florida, United States | Recruiting |
| Kymera Investigative Site | Miami, Florida, United States | Recruiting |
| Kymera Investigative Site | Miami, Florida, United States | Recruiting |
| Kymera Investigative Site | Miami Lakes, Florida, United States | Recruiting |
| Kymera Investigative Site | Tampa, Florida, United States | Recruiting |
| Kymera Investigative Site | East Point, Georgia, United States | Recruiting |
| Kymera Investigative Site | Iowa City, Iowa, United States | Recruiting |
+ 46 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07323654